Given the broad nature of PGE2 biologic activities and the differential involvement of EP receptors in mediating these activities, specific targeting of EP4 signaling should provide a more focused and possibly safer approach to anti-cancer therapy than inhibitors of the entire pathway leading to PGE2 production. The gene discussed is PTGER4; the disease is cancer.